Loading
A phase 1/2 trial of Belantamab mafodotin, Nirogacestat, Dostarlimab in multiple myeloma, run by GlaxoSmithKline, active and no longer recruiting.
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) is a phase 1/2 interventional study registered as NCT04126200 by GlaxoSmithKline, with 208 participants enrolled, started 2019-10-07 and due to reach its primary completion in 2025-04-17. Interventions recorded: Belantamab mafodotin, GSK3174998, Feladilimab, Nirogacestat, Dostarlimab. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Feladilimab, Belantamab mafodotin, GSK, Relapsed or refractory multiple myeloma.
Shares Nirogacestat, Belantamab mafodotin, GSK, Lenalidomide.
Shares Isatuximab, Belantamab mafodotin, GSK, Relapsed or refractory multiple myeloma.
Shares Nirogacestat, Belantamab mafodotin, GSK, Relapsed or refractory multiple myeloma.
Shares Nirogacestat, Belantamab mafodotin, GSK, Dexamethasone.
Shares Belantamab mafodotin, GSK, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Belantamab mafodotin, GSK, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Belantamab mafodotin, GSK, Dexamethasone, Relapsed or refractory multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/